Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Published:2019-07-02 Issue:9 Volume:36 Page:2450-2462
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Vandenbossche Joris,Jessner Wolfgang,van den Boer Maarten,Biewenga Jeike,Berke Jan Martin,Talloen Willem,De Zwart Loeckie,Snoeys Jan,Yogaratnam Jeysen

Funder

Janssen Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-019-01017-1.pdf

Reference14 articles.

1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.

2. Lavanchy D, Kane M. Global epidemiology of hepatitis B virus infection. In: Liaw YF, Zoulim F, editors. Hepatitis B virus in human diseases. Molecular and translational medicine. New York: Humana Press; 2016.

3. Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399–408.

4. Bourliere M. Hepatitis B treatment: could we extend the current treatment indication? Lancet Gastroenterol Hepatol. 2017;2:543–4.

5. Lam AM, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother. 2017;61:e00680–17.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial;The Lancet Gastroenterology & Hepatology;2023-09

2. Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment;The Journal of Clinical Pharmacology;2023-03-20

3. Overview of the development of HBV small molecule inhibitors;European Journal of Medicinal Chemistry;2023-03

4. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection;Gut;2023-01-25

5. Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB ‐506 from Phase 1 studies in healthy subjects and those with hepatitis B;Hepatology Communications;2022-10-04